AAAAAA

   
Results: 1-10 |
Results: 10
Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction
Authors: Nortvedt, MW Riise, T Myhr, KM Landtblom, AM Bakke, A Nyland, HI
Citation: Mw. Nortvedt et al., Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction, MULT SCLER, 7(4), 2001, pp. 231-235
Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension
Authors: Myhr, KM Riise, T Vedeler, C Nortvedt, MW Gronning, M Midgard, R Nyland, HI
Citation: Km. Myhr et al., Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension, MULT SCLER, 7(1), 2001, pp. 59-65
Quality of life as a predictor for change in disability in MS - Reply
Authors: Nortvedt, MW Riise, T Myhr, KM Nyland, HI
Citation: Mw. Nortvedt et al., Quality of life as a predictor for change in disability in MS - Reply, NEUROLOGY, 56(9), 2001, pp. 1250-1250
Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive
Authors: Myhr, KM Ross, C Nyland, HI Bendtzen, K Vedeler, CA
Citation: Km. Myhr et al., Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive, NEUROLOGY, 55(10), 2000, pp. 1569-1571
Quality of life as a predictor for change in disability in MS
Authors: Nortvedt, MW Riise, T Myhr, KM Nyland, HI
Citation: Mw. Nortvedt et al., Quality of life as a predictor for change in disability in MS, NEUROLOGY, 55(1), 2000, pp. 51-54
Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population
Authors: Nortvedt, MW Riise, T Myhr, KM Nyland, HI
Citation: Mw. Nortvedt et al., Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population, MED CARE, 38(10), 2000, pp. 1022-1028
Interferon-alpha 2a effects on complement activation and regulation in MS patients
Authors: Myhr, KM Sadallah, S Mollnes, TE Meri, S Nyland, HI Schifferli, J Vedeler, CA
Citation: Km. Myhr et al., Interferon-alpha 2a effects on complement activation and regulation in MS patients, ACT NEUR SC, 101(1), 2000, pp. 30-35
Type I interferons and the quality of life of multiple sclerosis patients.Results from a clinical trial on interferon alfa-2a
Authors: Nortvedt, MW Riise, T Myhr, KM Nyland, HI Hanestad, BR
Citation: Mw. Nortvedt et al., Type I interferons and the quality of life of multiple sclerosis patients.Results from a clinical trial on interferon alfa-2a, MULT SCLER, 5(5), 1999, pp. 317-322
Quality of life in multiple sclerosis - Measuring the disease effects morebroadly
Authors: Nortvedt, MW Riise, T Myhr, KM Nyland, HI
Citation: Mw. Nortvedt et al., Quality of life in multiple sclerosis - Measuring the disease effects morebroadly, NEUROLOGY, 53(5), 1999, pp. 1098-1103
Interferon-alpha 2a reduces MRI disease activity in relapsing-remitting multiple sclerosis
Authors: Myhr, KM Riise, T Lilleas, FEG Beiske, TG Celius, EG Edland, A Jensen, D Larsen, JP Nilsen, R Nortvedt, MW Smievoll, AI Vedeler, C Nyland, HI
Citation: Km. Myhr et al., Interferon-alpha 2a reduces MRI disease activity in relapsing-remitting multiple sclerosis, NEUROLOGY, 52(5), 1999, pp. 1049-1056
Risultati: 1-10 |